ESMO 2018 Major response to immunotherapy in early stage mismatch repair deficient colon cancer

ESMO 2018: Major response to immunotherapy in early stage mismatch repair deficient colon cancer

08:20 EDT 22 Oct 2018 | ecancermedicalscience

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO...

More From BioPortfolio on "ESMO 2018: Major response to immunotherapy in early stage mismatch repair deficient colon cancer"